Haisco Pharmaceutical Group (002653.SZ): HSK46575 tablet is approved for new indications in drug clinical trials.
Hisi Science (002653.SZ) announced that its subsidiary, Liaoning Hisi Science Pharmaceutical Co., Ltd., recently received the "Notification of Approval of Clinical Trial" issued by the National Medical Products Administration. The drug approved for trial this time is HSK46575 tablet, intended for the treatment of prostate cancer in combination with olaparib or in combination with docetaxel and prednisone tablets.
Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Liaoning Haisco Pharmaceutical Group Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug approved for clinical trial this time is HSK46575 tablets, with indications for use in combination with olaparib or in combination with docetaxel and prednisone tablets for the treatment of prostate cancer.
Related Articles
CT Enterprise (03839) plans to rename as "Zhengda Bio Holdings Limited"
TWINTEK (06182) has received resumption of trading guidance.
HOPEFLUENT (00733) issues a profit warning, expecting a year-end loss of HK$ 280 million to HK$ 330 million for shareholders.
CT Enterprise (03839) plans to rename as "Zhengda Bio Holdings Limited"
TWINTEK (06182) has received resumption of trading guidance.
HOPEFLUENT (00733) issues a profit warning, expecting a year-end loss of HK$ 280 million to HK$ 330 million for shareholders.
